Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, two stage, single period, single oral dose pharmacokinetic study of Remogliflozin etabonate tablet 100 mg and Remogliflozin etabonate tablet 250 mg of Glenmark pharmaceuticals ltd., India in normal, healthy, adult, human male subjects under fasting and/or fed condition

Next Previous
X
Search
Trial Profile

An open label, two stage, single period, single oral dose pharmacokinetic study of Remogliflozin etabonate tablet 100 mg and Remogliflozin etabonate tablet 250 mg of Glenmark pharmaceuticals ltd., India in normal, healthy, adult, human male subjects under fasting and/or fed condition

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remogliflozin etabonate (Primary)
  • Indications Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Glenmark Pharmaceuticals Ltd

    • Most Recent Events

    • 04 Oct 2019 Results published in the Clinical Pharmacokinetics
    • 08 Jan 2018 Status changed from not yet recruiting to completed.
    • 02 Jan 2018 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top